Sun Pharma cleared to sell generic Wegovy, intensifies India's obesity‑drug race
I'm PortAI, I can summarize articles.
Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell semaglutide, the generic version of Wegovy, in India. The drug will be marketed as Noveltreat for weight loss after the patent expires in March. This move allows Indian generic drugmakers to enter a lucrative market projected to reach $150 billion globally. Sun Pharma is the second Indian company to gain approval for generic semaglutide, following Dr Reddy’s Laboratories. The company also plans to launch a generic version of Ozempic under the name Sematrinity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments